Cargando…
Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609275/ https://www.ncbi.nlm.nih.gov/pubmed/30232463 http://dx.doi.org/10.1038/s41375-018-0241-7 |
| _version_ | 1783604996408868864 |
|---|---|
| author | Degryse, S. de Bock, C. E. Demeyer, S. Govaerts, I. Bornschein, S. Verbeke, D. Jacobs, K. Binos, S. Skerrett-Byrne, D. A. Murray, H. C. Verrills, N. M. Van Vlierberghe, P. Cools, J. Dun, M. D. |
| author_facet | Degryse, S. de Bock, C. E. Demeyer, S. Govaerts, I. Bornschein, S. Verbeke, D. Jacobs, K. Binos, S. Skerrett-Byrne, D. A. Murray, H. C. Verrills, N. M. Van Vlierberghe, P. Cools, J. Dun, M. D. |
| author_sort | Degryse, S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7609275 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76092752020-11-05 Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia Degryse, S. de Bock, C. E. Demeyer, S. Govaerts, I. Bornschein, S. Verbeke, D. Jacobs, K. Binos, S. Skerrett-Byrne, D. A. Murray, H. C. Verrills, N. M. Van Vlierberghe, P. Cools, J. Dun, M. D. Leukemia Correction Nature Publishing Group UK 2018-09-19 2018 /pmc/articles/PMC7609275/ /pubmed/30232463 http://dx.doi.org/10.1038/s41375-018-0241-7 Text en © The Author(s) 2018 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Correction Degryse, S. de Bock, C. E. Demeyer, S. Govaerts, I. Bornschein, S. Verbeke, D. Jacobs, K. Binos, S. Skerrett-Byrne, D. A. Murray, H. C. Verrills, N. M. Van Vlierberghe, P. Cools, J. Dun, M. D. Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia |
| title | Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia |
| title_full | Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia |
| title_fullStr | Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia |
| title_full_unstemmed | Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia |
| title_short | Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia |
| title_sort | correction: mutant jak3 phosphoproteomic profiling predicts synergism between jak3 inhibitors and mek/bcl2 inhibitors for the treatment of t-cell acute lymphoblastic leukemia |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609275/ https://www.ncbi.nlm.nih.gov/pubmed/30232463 http://dx.doi.org/10.1038/s41375-018-0241-7 |
| work_keys_str_mv | AT degryses correctionmutantjak3phosphoproteomicprofilingpredictssynergismbetweenjak3inhibitorsandmekbcl2inhibitorsforthetreatmentoftcellacutelymphoblasticleukemia AT debockce correctionmutantjak3phosphoproteomicprofilingpredictssynergismbetweenjak3inhibitorsandmekbcl2inhibitorsforthetreatmentoftcellacutelymphoblasticleukemia AT demeyers correctionmutantjak3phosphoproteomicprofilingpredictssynergismbetweenjak3inhibitorsandmekbcl2inhibitorsforthetreatmentoftcellacutelymphoblasticleukemia AT govaertsi correctionmutantjak3phosphoproteomicprofilingpredictssynergismbetweenjak3inhibitorsandmekbcl2inhibitorsforthetreatmentoftcellacutelymphoblasticleukemia AT bornscheins correctionmutantjak3phosphoproteomicprofilingpredictssynergismbetweenjak3inhibitorsandmekbcl2inhibitorsforthetreatmentoftcellacutelymphoblasticleukemia AT verbeked correctionmutantjak3phosphoproteomicprofilingpredictssynergismbetweenjak3inhibitorsandmekbcl2inhibitorsforthetreatmentoftcellacutelymphoblasticleukemia AT jacobsk correctionmutantjak3phosphoproteomicprofilingpredictssynergismbetweenjak3inhibitorsandmekbcl2inhibitorsforthetreatmentoftcellacutelymphoblasticleukemia AT binoss correctionmutantjak3phosphoproteomicprofilingpredictssynergismbetweenjak3inhibitorsandmekbcl2inhibitorsforthetreatmentoftcellacutelymphoblasticleukemia AT skerrettbyrneda correctionmutantjak3phosphoproteomicprofilingpredictssynergismbetweenjak3inhibitorsandmekbcl2inhibitorsforthetreatmentoftcellacutelymphoblasticleukemia AT murrayhc correctionmutantjak3phosphoproteomicprofilingpredictssynergismbetweenjak3inhibitorsandmekbcl2inhibitorsforthetreatmentoftcellacutelymphoblasticleukemia AT verrillsnm correctionmutantjak3phosphoproteomicprofilingpredictssynergismbetweenjak3inhibitorsandmekbcl2inhibitorsforthetreatmentoftcellacutelymphoblasticleukemia AT vanvlierberghep correctionmutantjak3phosphoproteomicprofilingpredictssynergismbetweenjak3inhibitorsandmekbcl2inhibitorsforthetreatmentoftcellacutelymphoblasticleukemia AT coolsj correctionmutantjak3phosphoproteomicprofilingpredictssynergismbetweenjak3inhibitorsandmekbcl2inhibitorsforthetreatmentoftcellacutelymphoblasticleukemia AT dunmd correctionmutantjak3phosphoproteomicprofilingpredictssynergismbetweenjak3inhibitorsandmekbcl2inhibitorsforthetreatmentoftcellacutelymphoblasticleukemia |